Table 2.
Drugs | Strain (n) | Treatment | –logEC50 (M) | Hill slope | Emax (%) |
---|---|---|---|---|---|
2fly | C57 (9) | Control | 8.26 ± 0.12 | 2.0 ± 0.3 | 96 ± 1 |
C57 (9) | l-NAME | 7.94 ± 0.10a | 1.3 ± 0.2a | 90 ± 4 | |
db/db (9) | Control | 8.07 ± 0.09 | 2.3 ± 0.3 | 98 ± 1 | |
db/db (9) | l-NAME | 7.95 ± 0.11 | 2.2 ± 0.3 | 92 ± 3 | |
ACh | C57 (6) | Control | 7.13 ± 0.10 | 1.2 ± 0.2 | 93 ± 2 |
C57 (6) | l-NAME | 6.97 ± 0.18 | 1.6 ± 0.3 | 52 ± 9a | |
db/db (6) | Control | 6.57 ± 0.18 | 1.0 ± 0.2 | 67 ± 6 | |
db/db (6) | l-NAME | 6.57 ± 0.43 | 1.4 ± 0.3 | 56 ± 12 | |
Nitroprusside | C57 (6) | Control | 7.86 ± 0.33 | 0.9 ± 0.1 | 93 ± 2 |
C57 (6) | l-NAME | 7.69 ± 0.16 | 1.3 ± 0.4 | 95 ± 5 | |
db/db (6) | Control | 7.27 ± 0.14 | 1.3 ± 0.4 | 90 ± 3 | |
db/db (6) | l-NAME | 7.05 ± 0.24 | 1.0 ± 0.2 | 91 ± 6 |
Values represent mean ± SE for n = number of mice.
Variables were determined by curve fitting data points from cumulative drug concentration–response relationships to four parameter logistic equation.
P < 0.05, l-NAME compared with control within strain, two-way anova (strain × artery treatment) followed by Bonferroni post hoc test.
Emax, maximum relaxation response where 100% is complete reversal of contraction. l-NAME (100 µM, 20 min).